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Abstract:
Background: Oral anticoagulant therapy (OAT) is used to prevent/treat thromboembolism. Major bleeding is common in patients on 
OAT; eg, warfarin increases intracranial hemorrhage (ICH) risk.
Case: A 71-year-old male on warfarin (to reduce stroke risk) presented at Accident and Emergency Minor Injuries Unit with headache 
after reportedly sounding ‘drunk’. On triage, the patient appeared lucid and well. However, International Normalized Ratio (INR) 
was 4.1. Head computed tomography (CT) indicated a large right-sided subdural hematoma. Prothrombin complex concentrate (PCC; 
  Beriplex® P/N, CSL Behring) with vitamin K normalized the INR within minutes of administration. The patient underwent neurosurgery 
without complications, and was discharged after 5 days, with no residual neurological symptoms.
Conclusions:  ICH  patients  can  present  with  no  neurological  signs.  In  OAT  patients  with  headache,  INR  must  be  established; 
if $3.0,   normalization of INR and head CT are essential. PCC is the best option to rapidly reverse anticoagulation and correct INR 
  pre-surgery.
Keywords: anticoagulation reversal, Beriplex® P/N, computed tomography, International Normalized Ratio, intracranial hemorrhage, 
prothrombin complex concentrateWong
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Introduction
Oral  anticoagulant  therapy  (OAT)  is  prescribed  to 
large  numbers  of  patients  for  the  prevention  and 
treatment  of  thromboembolic  disease.1  In  2001, 
approximately 500,000 people in the UK took OAT; 
the vitamin K antagonist warfarin was used in the large 
majority of these patients.2 Warfarin has a narrow ther-
apeutic  index;  thrombosis  risk  increases  when  the 
International Normalized Ratio (INR) falls below 2.0 
and serious bleeding risk increases when the INR rises 
above 4.0. As a result, major bleeding is a common 
problem in people taking OAT, occurring at a rate of 
2.4%–8.1% per patient-year.3 Intracranial hemorrhage 
(ICH)  is  perhaps  the  most  serious  complication  of 
OAT; warfarin therapy increases both the likelihood of 
suffering ICH and the mortality associated with it.4,5 
Intracranial  hemorrhage  associated  with  OAT  can 
be  divided  into  the  following  types:  intracerebral/
intraparenchymal, subdural/epidural (acute or chronic), 
and subarachnoid. Intracerebral hemorrhage accounts 
for around 70% of OAT-associated ICH, with subdural 
hematoma making up the bulk of the remainder.5,6
Current therapeutic options for reversal of OAT 
in patients with major hemorrhage are fresh   frozen 
plasma  (FFP),  prothrombin  complex  concentrate 
(PCC;  which  includes  the  vitamin-K    dependent 
coagulation factors II, VII, IX and X) and   recombinant 
factor  VIIa,  administered  in  combination  with 
vitamin K.7–10 Although FFP is still often used, PCC 
offers substantial benefits over FFP and is the ‘gold 
  standard’  therapy.11  Whereas  PCC  can  be  rapidly 
prepared and corrects vitamin K antagonist-induced 
impairment  of  hemostasis  within  30  minutes  of 
administration, FFP must be thawed and large volumes 
infused,  leading  to  delayed  and  often    inadequate 
  correction  of  anticoagulation.12–14  PCC  also  offers 
safety advantages over FFP, such as virus reduction/
inactivation and a low risk of thrombotic events.13,15,16 
FFP  is    associated  with  transfusion-related  lung 
injury, allergy/anaphylaxis, hemolysis, and bacterial 
  contamination/sepsis.17  A    randomized,    multicenter, 
Phase IIIb trial (NCT00803101) is   currently evaluating 
the  efficacy  and  safety  of  the  PCC  Beriplex®  P/N 
compared  with  FFP  in  patients  taking  OAT  who 
require emergency surgery or invasive intervention. 
This study has the proportion of subjects experienc-
ing a rapid decrease in INR as a primary endpoint and 
is due to complete in mid-2011.
The  case  described  below  highlights  that  even 
in the absence of neurological signs, a slow-onset 
headache  in  a  patient  taking  OAT  might  indicate 
  underlying  ICH.  In  this  scenario,  head  computed 
tomography (CT) is required for differential diagnosis, 
and administration of PCC can rapidly reverse OAT 
to enable successful neurosurgery.
case Report
A  71-year-old  white  British  male  (weight:  80  kg, 
height: 178 cm) presented at night to our Accident 
and Emergency Minor Injuries Unit with a headache. 
Although the patient felt he was fine, his son reported 
that he sounded ‘drunk’ in conversation. The patient 
had  been  experiencing  intermittent  ‘waves’  of 
headache that had slowly worsened over the preceding 
five days but were not debilitating. He graded the 
headache  as  8/10  at  its  worst.  Simple  analgesia 
helped with the pain initially, but had become less 
effective. The headache had a slow onset and was 
focused around both orbits and the frontal area, with 
no radiation. No nausea, vomiting, changes in vision, 
systemic symptoms or deterioration of general health 
were reported. The patient had no history of falls or 
head injury. On initial triage by a nurse, the patient 
was speaking in full sentences, did not appear con-
fused and looked well. He was given two tablets of 
co-codamol (30/500).
The  patient’s  medical  history  included  atrial 
fibrillation, hypertension, glaucoma, gastroesophageal 
reflux, and hypothyroidism. The patient was taking 
warfarin (4 mg per day) as part of his   regular medi-
cation  to  reduce  stroke  risk  associated  with  atrial 
fibrillation.  Medication  history  included  ranitidine, 
bendroflumethiazide,  diltiazem,  levothyroxine,  and 
no  known  drug  allergies.  Review  of    systems  and 
  family  history  were  negative.  The  patient  was  an 
  ex-smoker (stopped smoking 20 cigarettes per day 
10 years ago) and consumed little alcohol. He was 
living at home with his wife and stated that he was 
stressed by her recent admittance to our hospital with 
fast atrial fibrillation.
On  examination,  the  patient’s  vital  signs  were: 
blood pressure, 138/82 mmHg; heart rate, 82 beats/min 
(irregular); respiratory rate, 19 breaths/min; tempera-
ture, 35.4 °C; and oxygen saturation, 97% (on air). The 
patient’s chest was clear, with   normal breath sounds. 
Heart sounds (in rate-controlled atrial fibrillation) were Warfarin reversal in intracranial hemorrhage
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also normal, jugular venous pressure was not raised, 
and there were no signs of heart failure. The abdo-
men was soft and not tender.   Neurological examina-
tion showed power was 5/5 in all limbs, with normal 
tone, sensation and reflexes. Extraocular movements 
were normal, with direct and indirect pupil reactions 
bilaterally. Mini-mental state examination score was 
10/10. Cerebellar function was normal and there were 
no obvious signs of an intracranial bleed. Immediately 
after examination, the patient vomited. This was most 
likely due to the codeine given for analgesia rather 
than  indicating  raised  intracranial  pressure  because 
the patient had not vomited up to that point and did not 
vomit again afterwards. However, considering that the 
patient was normally fit and healthy, had reportedly 
sounded ‘drunk’, and was taking warfarin, a possible 
intracranial bleed was suspected.
Head  CT  indicated  a  large  right-sided  acute  on 
chronic subdural hematoma (maximum depth, 1.9 cm) 
occupying  the  frontal,  parietal  and  temporal  con-
vexities,  and  potentially  also  a  small  subarachnoid 
hemorrhage (Fig. 1). No hydrocephalus or recent infarct 
were observed. Blood tests at presentation returned an 
INR of 4.1, a prothrombin time of 51 seconds, and an 
activated partial thromboplastin time ratio of 1.69.
Because  reversal  of  warfarin  and  rapid  correc-
tion  of  INR  were  required  before  surgery,  10  mg 
of vitamin K and 40 IU/kg of PCC (Beriplex® P/N; 
CSL    Behring,  Marburg,  Germany)  were  adminis-
tered intravenously. Blood tests subsequently showed 
an INR of 1.0, at which point the patient underwent 
emergency transfer to the Neurosurgery Department 
at King’s   College Hospital, London for surgical inter-
vention. The patient was operated on approximately 
10 hours after diagnosis of the intracranial bleed and 
there were no bleeding complications during surgery.
The  patient’s  outcome  was  excellent—he  was 
discharged  5  days  after  surgery,  with  no  residual 
  neurological symptoms apparent.
Discussion
Guidelines from the American College of   Emergency 
Physicians  recommend  that  head  CT  should  be 
  performed in the Emergency Department in patients 
presenting with a headache if this is accompanied 
by new abnormal neurological findings or is new, 
  sudden-onset,  and  severe.18  The  case  described 
here, however, demonstrates that patients with large 
  subdural hematomas may present with a slow-onset 
headache and no neurological symptoms. Without 
further investigation, such patients might be given 
analgesic treatment and discharged, with potentially 
fatal consequences. In patients with a headache who 
are taking OAT and are therefore at increased risk of 
major bleeding, it is imperative to establish the INR 
(even if the patient’s INR record book is up-to-date). 
If the INR is $3.0, the patient should be admitted 
for normalization of INR and head CT should be 
performed in order to try and identify a treatable 
lesion.  This  is  a  generalized  approach,  however, 
and it is important to be aware that patients with 
an INR ,3.0 may also suffer an ICH. Sound clini-
cal judgment and availability of hospital resources 
are crucial in delivering effective care on a case-by-
case basis.
Before  surgery,  rapid  reduction  of  the  INR  is 
required  (normalized  INR  is  #1.3).  In  line  with 
  current guidelines, the protocol in our hospital is to 
use Beriplex® P/N to achieve this and stop bleeding 
in  patients  taking  OAT.  Approximate  dosing  of 
  Beriplex®  P/N  can  be  calculated  based  on  patient 
bodyweight, the INR before treatment, and the target 
INR. Resuscitation nurses at our hospital are trained 
in the administration of Beriplex® P/N—familiarity 
of  nurses  and  hematology  staff  with  the  protocol 
Figure  1.  Computed  tomography  indicated  a  large  right-sided  acute 
on  chronic  subdural  hematoma  (maximum  depth,  1.9  cm)    occupying 
the  frontal,  parietal  and  temporal  convexities,  and  a  possible  small 
  subarachnoid hemorrhage.Wong
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is  key  in  enabling  urgent  treatment.  Despite  this, 
however, treatment with FFP was initially   suggested 
and  approval  had  to  be  sought  from  the  on-call 
hematology consultant before   Beriplex® P/N could be 
given. Once administered, Beriplex® P/N   corrected 
the  vitamin  K  antagonist-induced  impairment  of 
hemostasis within minutes, enabling the patient to be 
transferred and operated on. The neurosurgical team 
was grateful for our effective pre-transfer care and 
communication, both being important factors in the 
successful outcome of this case.
In emergency bleeding situations it is vital that any 
barriers to early treatment are removed. In this case, 
administrative barriers prevented earlier use of   Beriplex® 
P/N. This delayed the second INR reading, which is 
critical for deciding when a patient with major bleeding 
can be transferred for emergency   surgery.   Following 
this  case,  our  hospital  implemented  a  management 
Figure 2. Management algorithm (A) and prothrombin complex concentrate (pCC) request form (B) implemented at Maidstone and Tunbridge Wells NHS 
Trust, UK to help Accident and emergency staff in providing pCC for warfarin reversal. 
Abbreviations:  CT,  computed  tomography;  DIC,  disseminated  intravascular  coagulation;  GI,  gastrointestinal;  Hb,  hemoglobin;  INR,  International 
  Normalized Ratio; i.v., intravenous; mmHg, millimeters of mercury; NHS, National Health Service; pCC, prothrombin complex concentrate.
Patient on warfarin (or warfarin
substitute) with raised INR? 
Major/life-threatening bleeding?*
– Intracranial (CT evidence)
– Retroperitoneal (CT evidence)
– Intra-ocular
– Muscle haematoma associated with
   compartment syndrome
– Pericardial
– Intra-articular (traumatic)
– Any invasive procedure to stop
   bleeding
– Any emergency procedure with high
   risk of bleeding
– Systolic <90 mmHg
– Drop of >2 g/dL in Hb level
PCC indicated
– Complete request form and send to
   transfusion laboratory who will
   arrange PCC as soon as possible
   after authorisation from consultant in
   charge of patient’s care
– Give 5 mg i.v. vitamin K
– Measure INR 4–6 hours after
  administration of PCC
– Record documentation carefully in the
  patient notes
If ongoing bleeding/worsening
compromise despite PCC, consider:
– DIC
– Liver disease
– Inadequate dose of PCC
Discuss with haematology
Surgery
– For surgery where there is no risk of severe bleeding, surgery can be performed with an INR of <2.5.
– For surgery where there is a risk of severe bleeding, warfarin should be stopped 3 days prior to
  surgery +/– Fragmin cover.
– Where it is necessary to continue anticoagulation, eg, risk of life-threatening thromboembolism, the
  INR should be reduced to <2.5 and heparin therapy should be started.
– If surgery is required and warfarin cannot be stopped 3 days beforehand, anticoagulation should be
  reversed with low-dose vitamin K. Only if surgery is emergency, life-threatening, or there is a high risk
  of bleeding and blood loss, should PCC be used.
– The timing for re-instating warfarin therapy depends on the risk of post-operative haemorrhage.
  In most instances warfarin treatment can be re-started as soon as the patient has an oral intake.
*  The above is not set in stone; clinical judgement should always be made with regards to benefit
  versus risk. If unsure, senior and haematology advice should be sought.
Minor
bleeding?*
Raised INR but no
bleeding
INR >7
1–2 mg i.v. vitamin K*
INR >5
Consider i.v. vitamin K if
high risk (elderly, previous
GI bleed, etc.)*
INR <5
Withold warfarin or
reduce dose until INR in
therapeutic range
2–5 mg i.v.
vitamin K
Yes
Yes
No No
Yes
Also note
AWarfarin reversal in intracranial hemorrhage
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algorithm  to  help Accident  and    Emergency  staff  in 
providing PCC for warfarin reversal; this algorithm and 
the PCC request form are shown in   Figure 2. Although 
this algorithm states to ‘measure INR 4–6 hours after 
administration of PCC’, it is   important to be aware that 
PCC  typically  normalizes  INR  much  more  quickly 
than this (ie, within 30   minutes of administration).19 
Valuable time could also be saved by training of on-call 
laboratory staff to accept direct referrals (rather than 
via the on-call consultant hematologist).
Other important factors in enabling early treatment 
include rapid triage in Accident and Emergency and 
taking  an  accurate  medical  history.  The  latter  is 
especially important when assessing patients with a 
headache;18 in this case, ongoing warfarin therapy indi-
cated a possible intracranial bleed. Furthermore, this 
Maidstone and Tunbridge Wells NHS Trust
REQUEST FOR PROTHROMBIN COMPLEX CONCENTRATE (PCC)
INDICATION
PCC is licensed for major or life-threatening bleeding secondary to warfarin-induced coagulopathy.
PCC is indicated if one or more of the following is present:
The laboratory will calculate the correct dose required and will dispense it.
Patient name:
Hospital no.:
Weight (kg):
Date of birth:
INR:
Please ensure that 5 mg of i.v. vitamin K is administered as soon as possible to provide sustained
correction of coagulation.
PCC is a mixture of factors II, VII, IX and X, along with Proteins C and S, and is derived from human plasma from
multiple donors. It is to be treated like any other blood product, along with the risk they entail.
Side effects include increased risk of thrombotic events (both venous and arterial) and careful consideration of
risk versus benefit should be made.
PCC contains heparin so should not be used in patients with a previous history of heparin-induced
thrombocytopaenia.
The use of PCC will need to be authorised by the CONSULTANT in charge of the care of the patient and this
should be recorded on this request (below) and on the hospital notes. PCC will not be issued unless the
consultant in charge of the patient agrees to its release.
(Please tick)
Intracranial (CT evidence)
Retroperitoneal (CT evidence)
Intra-ocular
Muscle haematoma associated with compartment syndrome
Pericardial
Intra-articular (traumatic)
Any invasive procedure to stop bleeding
Any emergency procedure with high risk of bleeding
Systolic <90 mmHg with blood loss
Drop of >2 g/dL in Hb level
Name of consultant:
Date and time of authorisation:
If there are specific concerns about the use of PCC, or if there is ongoing bleeding despite the use of PCC,
discussion with the on-call haematology team is advised.
Source of bleeding:
B
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case highlights the importance of taking a   collateral 
history  from  a  close  relative  or  friend  in  elderly 
patients who want to maintain their independence. 
Neurological evaluation is essential as patients with 
ICH may decompensate rapidly.
In  summary,  this  case  shows  that  patients  with 
ICH  may  present  with  no  neurological  signs.  In 
patients  who  are  taking  OAT,  a  headache  and  an 
elevated INR ($3.0) might indicate ICH; therefore, 
normalization  of  INR  and  head  CT  are  essential. 
PCC is widely considered to be the best option for 
rapid anticoagulation reversal and correction of INR. 
This  enables  potentially  life-saving  neurosurgery 
to be   performed with minimal delay, increasing the 
likelihood of a positive outcome.
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